Sclerosing alcohol injections for the management of intermetatarsal neuromas: a systematic review by Santos, Derek et al.
Accepted Manuscript
Title: Sclerosing alcohol injections for the management of
intermetatarsal neuromas: a systematic review
Authors: Derek Santos, Graeme Morrison, Andrea Coda
PII: S0958-2592(17)30157-8
DOI: https://doi.org/10.1016/j.foot.2017.12.003
Reference: YFOOT 1517
To appear in: The Foot
Received date: 14-8-2017
Revised date: 18-12-2017
Accepted date: 23-12-2017
Please cite this article as: Santos Derek, Morrison Graeme, Coda Andrea.Sclerosing
alcohol injections for the management of intermetatarsal neuromas: a systematic
review.The Foot https://doi.org/10.1016/j.foot.2017.12.003
This is a PDF file of an unedited manuscript that has been accepted for publication.
As a service to our customers we are providing this early version of the manuscript.
The manuscript will undergo copyediting, typesetting, and review of the resulting proof
before it is published in its final form. Please note that during the production process
errors may be discovered which could affect the content, and all legal disclaimers that
apply to the journal pertain.
1 
 
 
Sclerosing alcohol injections for the management of intermetatarsal neuromas: a systematic review 
A Dr Derek Santos * - PhD <Deg>MSc</Deg>, BSc (Hons) dsantos@qmu.ac.ukA Mr Graeme Morrison - MSc, BSc (Hons) 
gmorrison@qmu.ac.ukB Dr Andrea Coda PhD, BSc (Hons) Andrea.Coda@uon.edu.au 
A- School of Health Sciences, Podiatry, Queen Margaret University, Edinburgh, UK, EH21 6UU., Edinburgh, UK 
B- The University of Newcastle, School of Health Sciences, Faculty of Health and Medicine - Health Precinct, BE154, PO Box 127. Ourimbah, 
NSW, 2258, Australia. Tel: 0243484507 
 
* - Corresponding author. 
Highlights 
► This review found insufficient high-quality research evidence to afford conclusions on the management of intermetatarsal neuroma with 
alcohol sclerosing agent injections.  
► Alcohol injections appear to be safe although a short-term side effect of a flogistic reaction may occur.  
► Given the overall lack of high level evidence to support the effective management of intermetatarsal neuroma, a staged management approach 
may be a logical treatment option, until further research evidence to support the respective treatment becomes available. Alcohol injections could 
be included in this stepwise approach when other more evidence-based treatment fail. 
ABSTRACT 
An intermetatarsal neuroma is a plantar digital neuritis causing metatarsalgia of the affected inter-metatarsal space. At present the evidence to support the 
management of the condition is poor with only some quality evidence supporting the short-term management of intermetatarsal neuromas using steroid 
injections. Some authors have supported the use of alcohol sclerosing intra-lesional injections to treat intermetatarsal neuromas. Following a search of the 
evidence 11 articles were identified. The systematic review found that alcohol injections appear to be safe although some papers report a short-term side 
effect of a flogistic reaction and there are variances in the alcohol concentration used and guiding verses not guiding the injection using ultrasound imaging. 
Some of the evidence may suggest a sclerosing histological effect of the nerve. However, all the studies reviewed present a research design offering a low 
level of evidence that is open to methodological biases and interpretation. Thus, this review found insufficient high-quality research evidence to afford 
conclusions on the management of intermetatarsal neuromas with alcohol sclerosing agent injections. 
 
Abbreviations: VAS , Visual Analogue Scale; QoL: Quality of life; RCT: Randomised controlled trial 
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1 Introduction 
Plantar interdigital neuroma was first described by Civinini in 1835 and later by Durlacher in 1845.[1] In 1876 Morton presented 12 case studies 
of neuralgic pain affecting the fourth intermetatarsal space. The same paper also commented on a further 3 cases (although not in any depth).[2] 
Although most papers refer to Morton’s neuroma when describing any neuroma in the forefoot, a more precise description would be 
intermetartarsal neuroma since Morton only referred to the 3rd/4th intermetartarsal space. Thus, the condition now commonly known as Morton’s 
neuroma or intermetatarsal neuroma is described as an entrapment or degenerative neuropathy secondary to mechanically induced compression 
of the intermetatarsal/interdigital nerve as it traverses under the transverse intermetatarsal ligament.[3-7] 
Intermetatarsal neuromas are diagnosed clinically following manual tests that reproduce the symptoms [1,8-10] and confirmed by advanced 
diagnostic investigations which may include ultrasound imaging[11-15] or Magnetic Resonance Imaging techniques.[16-21] Advanced 
diagnostic investigations have suggested that intermetatarsal neuromas become symptomatic when the transverse diameter is 5mm or 
more.[13,19-21] 
The is a lack of current evidence to support effective management of intermetatarsal neuromas although steroid injection appears to be supported 
by higher level evidence with a number of randomised control studies although long-term evidence is lacking.[22] 
2 Background 
3 Definition 
Intermetatarsal neuromas are described as a common neuralgic pain affecting the forefoot. The inter-metatarsal space between the 3rd/4th is most 
typically affected followed by inter-metatarsal spaces 2nd/3rd, 1st/2nd and 4th/5th.[22-29] 
Epidemiology 
Both feet appear to be equally affected however it is uncommon to find cases of bilateral presentation.[22] Similarly, it is not typical to find 
more than one neuroma affecting the same foot.[22] With regards to gender the condition appears to be 8-10 times more prevalent in females 
than males with a mean age distribution of 45-50 years.[30-32] The third web space is most commonly affected with the first and fourth rarely 
affected.[32] 
Symptoms 
Patients usually present complaining of a sharp, neuralgic, lancing pain, severe in onset that occurs suddenly when walking, especially with 
certain shoes which usually have a narrow toe-box. Some patients report that they have to stop walking, take their shoe off and massage or 
manipulate the toes to achieve some relief of symptoms. Other reported symptoms are described as tingling or burning sensation.[32] In the 
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worst cases, patients often report significant pain that can be debilitating and affect the person’s quality of life with regards to limitations in 
ambulation.[3] 
Diagnosis 
Diagnosis is usually based on clinical examination which has been reported to have good clinical specificity, with diagnostic investigations used 
in cases where clinical diagnosis is not clear and for those progressing for surgical intervention.[33,34] With regards to clinical examination, 
using more than one clinical test to confirm the diagnosis has proved more effective.[34,35] The most commonly used advanced diagnostic 
modality for diagnosis of intermetatarsal neuromas is ultrasound imaging which has been shown to be sensitive and reliable.[36] 
3.1.1 Animal studies 
A study by Rengachary et al (1983) used graded concentrations of alcohol (5, 10, 25, and 50%) that was injected extra and intra-neurally using 
56 rats sacrificed at 25 days. No control group was used. The degree of nerve destruction was graded in the range of 1 to 4 depending on the 
percentage of axons in the studies specimen showing pathological changes (Grade 1: 25% of axons showed pathological damage; Grade 2: 50% 
of axons showed pathological damage; Grade 3: 75% of axons showed pathological damage; and Grade 4: 100% of axons showed pathological 
damage). All extra-neural injections showed no histological neural changes, however, intra-neural injections showed noticeable destruction and 
this was dependant on concentration used. At five to ten percent of alcohol concentration no intra-neural damage was observed. At 25% 
concentration Grade 1 changes was reported and at 50% concentration Grade 2 changes were seen.[37] Another study by Mazoch et al (2014) 
also used the sciatic nerve in 22 rats as a model to evaluate the effects of alcohol injections in nerve tissue as a potential model for treatment of 
intermetatarsal neuromas.[38] Different concentrations of alcohol injections (that is, 4%, 20% and 30%) with 0.5% Marcaine was used and 
injected intra-neural, peri-neural and peri-muscular. Mazoch et al (2014) concluded that regardless of the concentration of alcohol or technique 
used there was no histologic evidence of cell necrosis or inflammation in the nerve tissue. However, all the rats were sacrificed at 10 days post 
injection, a higher range of concentrations could have been used and no repeated injections were carried out to simulate clinical studies/practice 
hence, it is possible that not enough time was allowed for the nerve tissue changes to occur or maybe that repeated injections are required to 
achieve pathological nerve effects. 
Management 
Symptomatic neuromas cause forefoot neuralgic pain radiating to the affected digits.[9,10] These are initially treated with conservative measures 
including patient education, pads, orthosis, footwear modifications and steroid injections.[1,8] Bennett et al. (1995) found that 50% (n=57/115) 
of subjects benefited from footwear modifications, pads and patient education. A Cochrane’s review found no evidence to support the use of 
orthosis.[22] 
Cortisone Injection Therapy 
AC
CE
PT
ED
 M
AN
US
CR
IPT
4 
 
Steroid injections are routinely used as an initial or adjunct treatment choice in conjunction with stretching, footwear advice and foot orthosis 
management. In retrospective studies Bennett (1995) found that 47% of those who received a steroid injection demonstrated an improvement in 
symptoms and Greenfield (1984) found that most were asymptomatic after two years; however, other retrospective studies have reported poor 
outcomes with steroid injections.[8,30,39] Rasmussen (1996) conducted a retrospective study involving 43 patients (51 feet) and found that in 
47% (n=24 feet) surgery was later required.[39] However, these retrospective studies should be interpreted with caution as they were not RCTs 
and their internal validity may be questioned. 
Thomson et al (2013) carried out a pragmatic, patient blinded RCT within a hospital orthopaedic setting. A total of 131 patients were recruited 
and randomised into a placebo group (receiving 2mL 1% lignocaine alone) and trial group (receiving 1mL methylprednisolone [40mg] and 1mL 
2% lignocaine). A diagnostic ultrasound was used to confirm the presence of a neuroma and all injections were guide by sonography. The 
clinical outcome measures used was a visual analogue scale (VAS) and quality of life. A clinical and statistical difference was reported by one 
and three months with improvements in the trial group suggesting that steroid injections are effective by up to three months with the size of the 
lesion not influencing the treatment effect.[40] However, more long term studies are needed to assess the long term effects of steroid injections. 
With regards to steroid injections, there may be a risk of ``steroid flare'', anaphylaxis, skin atrophy or altered pigmentation with the evidence 
suggesting that steroid injections are of limited value providing short to medium term relief for patients awaiting surgery.[22,23,40-43] 
Summary of Management 
In conclusion to the overall management for intermetatarsal neuromas, where conservative measures fail there is no other options available but 
surgical management, although there is still debate with regards to the best surgical technique, and there are also complications and failure rates 
associated with these procedures.[22] Thus, despite this staged management approach, the current evidence-base for the effectiveness of 
conservative and surgical management of intermetatarsal neuromas is still insufficient.[22] 
 
Methods 
Justification for Systematic Review 
As a consequence, more research evidence is required to support clinical guidelines, not only is more research evidence emerging with regards to 
the already established clinical treatments for intermetatarsal neuromas but also potential new treatments to manage this condition are being 
explored. Dockery in 1999 reported the first study using alcohol injections to conservatively manage intermetatarsal neuroma with this method 
then gaining popularity with numerous publications since then.[9] This review will critically appraise current evidence for the management of 
intermetatarsal neuromas with alcohol injections. 
Review Question 
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PICO (population, intervention, comparison and outcome) format was used to define the reviews research question as follows: Does alcohol 
injections [Intervention] provide effective clinical outcomes [Outcome] compared to other treatments [Comparison] for the treatment of 
intermetatarsal neuromas [Population]? 
Search Strategy 
An electronic search of the Cochrane’s Group Trials register, EBSCO Host Research Databases (MEDLINE and CINAHL Plus) was carried out 
on 26th June 2017.’ EBSCO Host Research Databases (MEDLINE and CINAHL Plus) was searched 1981 to 2017. The PICO search strategy 
allowed the development of the search strategy and the population and intervention was used with outcome and comparisons left open to 
increase numbers identified by search strategy. The references of all selected papers were also screened. 
MEDLINE and CINAHL Plus Search Strategy 
The following search strategy was carried out: 1)Morto*; 2) interdigital OR inter-digital OR plantar; 3) neurom*; 4) neur*; 5) 1 OR 2; 6) 3 OR 
4; 7) 5 AND 6; 8) alcohol; 10) 7 AND 8 
Cochrane’s Neuromuscular Disease Group Trials register 
The following search strategy was carried out: Morton OR Morton’s AND neuroma OR neuromas. This was used as the number of publications 
in the Cochranes library are limited and the search was kept as open as possible. 
Review methods 
Two reviewers (DS and AC) independently screened all titles and abstracts for studies identified by the search. Full text papers of potentially 
eligible studies were retrieved by DS and these were independently screened by DS and AC. Authorship and results were not masked. Any 
disagreements between the two authors regarding full-text inclusion were resolved by a third reviewer (GM). However, no disagreements 
occurred between the two reviewers. 
DS extracted data from included studies using a standardised pilot tested form. AC checked all the extracted data. If there were any absent or 
uncertain information, study authors were contacted. Inconsistencies in data extraction were discussed between DS and AC and, if needed, 
through arbitration by GM. Risk of bias of each included study was rated independently by DS and AC using the following criteria described in 
the Cochrane Handbook for Systematic Reviews of Interventions.[44] 
1. Sequence generation 
2. Allocation of concealment 
3. Blinding of participants, personnel and outcome assessor 
4. Incomplete outcome data 
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5. Selective outcome reporting 
6. Other sources data 
For each criterion ‘High’ indicates a high risk of bias, ‘Low’ indicates a low risk of bias and ‘unclear’ identifies an ambiguous or unclear risk of 
bias. 
Inclusion Criteria 
The population was patients with a clear diagnosis of intermetatarsal neuroma or its synonyms either clinically and/or using diagnostic imaging. 
The intervention was any concentration of alcohol injection either guided or non-guided. The comparator was any current reported treatment for 
intermetatarsal neuroma. The outcome was the Visual Analogue Scale (VAS) and/or any other quality of life or satisfaction tool. Finally, the 
study designs were randomised control studies (RCT), cohort and case-series/case-control studies. Studies other than RCTs were included as 
previous Cochranes reviews have not identified any RCTs using alcohol injections. 
Exclusion Criteria 
Articles or abstracts not written in English. 
Results from search strategy 
Following the electronic searches 46 papers were identified, with the Cochrane’s Group Trials register proving 1 systematic review and EBSCO 
Host Research Databases (MEDLINE and CINAHL Plus) 45 articles. No duplicates were identified by the search engines. The titles and 
abstracts were read by both reviewers independently and following consultation 34 papers were eliminated leaving the remaining 12 articles. 
One of the articles with an abstract in English was written in Italian, both reviewers agreed that this was a key article, and should be translated 
and included despite the set exclusion criteria.[45] The full text articles were then independently read and following discussion four more articles 
were excluded (one was a study using animals and three were classified as reviews or commentaries or proceedings) (Table 1). A total of seven 
articles were selected at this point. Following examination of the reference list of the papers a further four papers were selected that had evaded 
the electronic search process and following reading and further discussions these were also included. Thus, a total 11 studies were included in 
this systematic review. Figure 1 summarises the selection process, Table 2 the methodological breakdown of the studies and Table 3 the 
evaluation of bias. 
Methodological bias 
The risk of bias of included studies was independently assessed by DS, AC and GM using criteria described in the Cochrane Handbook for 
Systematic Reviews of Interventions. As reported in Table 3, the majority of studies included in this systematic review have been classified at AC
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potential high risk of bias. This is mostly due to lack of RCT currently available in this topic, which impacted domains such as allocation 
concealment, blinding of participant, study personnel and outcome assessors. 
4 Discussion 
4.1. Clinical studies 
Dockery (1999) first reported the prospective analysis of 100 patients with intermetatarsal neuroma who had been treated with intra-lesional 
injections of 4% alcohol and 0.5% bupivacaine hydrochloride with (1:200,000) adrenalin under ultrasound guidance. Each patient received a 
minimum of three and a maximum of seven injections at 5-10 day intervals. Follow-up after the last injection was between six months and two 
years. Of the 100 patients 82% reported complete resolution of their symptoms, 7% reported some improvement and 11% reported no 
improvement. The 11% of patients where the treatment failed were referred for surgery and an enlarged neuroma was reported by pathology for 
each patient.[9] Although the results for complete resolution of symptoms are good this study has a number of limitations with regards to 
internal and external validity. The study did not have placebo-control groups, no process of randomisation, no validated outcome measurement 
tool, some subjects received three injections and others seven, and outcome was recorded at different intervals with some patients reporting at 
six months and others at two years, hence the reporting could be biased by issues of memory recall and lifestyle modifications. All these issues 
affect the internal validity. Furthermore, all results were descriptive using percentages and no inferential statistics were used. Thus, this affects 
the external validity of the study as the results can only be applied to the studied population and not used to generalise the findings to other 
populations. 
A small study of 23 subjects was reported by Masalla et al. (2001) using 30% alcohol and 2% carbocaine hydrochloride with (1:200,000) 
adrenalin for intra-lesional injections under ultrasound guidance. The study reported a 91% resolution of all symptoms.[45] The methodology for 
the study was very similar to that used by Dockery (1999) other than the injection interval which was seven days. Hence, the same internal and 
external validity issues are applicable. The higher complete resolution rate could be related to the use of a higher concentration of alcohol 
solution. 
Fanucci et al. (2004) also used 30% alcohol and 2% carbocaine hydrochloride with (1:200,000) adrenalin for intra-lesional injections under 
ultrasound guidance. A total of 40 subjects received four injections at 15-day intervals to avoid strong flogistic reactions1 and follow-up was at 
ten months.[1] In addition, a ranked outcome measurement tool designed to record outcome for management of intermetatarsal neuroma was 
used.[46] At ten months follow-up the study reported complete satisfaction for 53% (n=21), 23% (n=9) reported satisfied, but with minor 
complications, 15% (n=6) were satisfied with major complications, and 10% (n=4) patients were dissatisfied and underwent surgery.[1] The 
methodological approach of Fanucci et al. (2004) was a great improvement on previous studies although no randomisation, placebo-control 
groups or inferential statistics were used, thus, affecting the internal and external validity of the findings. 
Hyer et al. (2005) studied six patients with eight neuromas with a mean follow-up of 365 days after weekly 3-9 injections of 4% alcohol and 
0.5% bupivicaine hydrochloride solution depending on patients. VAS was used to report outcomes and similar results to above were observed. 
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VAS mean pain reduction was 6.123.2 with five of six patients saying they would recommend to a friend as a measure of satisfaction.[47] 
Apart from the limitations reported above for the other studies this was also a pilot study with a small number of subjects. Overall, the results 
have low internal and external validity. 
A larger study by Musson et al (2012) involving 92 patients, although 12 had treatment for bilateral neuromas, injected 20% alcohol with 0.25% 
bupivacaine.[48] All neuromas were clinically and sonographically confirmed and all injections were carried out using ultrasound guided 
technique. After attrition due to incomplete records 75 patients took part in the study. Sixty-six percent (n=55) showed complete or partial relief 
of symptoms and the treatment was generally well tolerated with only 2% (n=2) of adverse events, although in one case the patient had an 
allergic reaction. The authors commented that the study design was a limitation because it was retrospective and there was no control group for 
comparison. However, their study suggested that the size of the lesion was not a significant factor in the outcome of the treatment and hence can 
be used to treat any neuroma irrespective of size although more evidence is required. 
A study, by Mozena et al. (2007) studied 42 subjects (49 intermetatarsal neuromas). All subjects were diagnosed by clinical examination only 
and received three to seven injections of 4% alcohol and bupivacaine hydrochloride every two weeks with 2-24 months follow-up. Complete 
resolution was achieved in 33% (n=16) and 29% (n=14) had improved symptoms. Also multiple injections up to a total of five was most 
effective with 7% (n=3) suffering a flogistic reaction which resolved in two days.[49] This study suggested that the treatment of intermetatarsal 
neuroma with alcohol injections was not as effective although it also suffered from all the internal and external validity issues mentioned earlier. 
In addition, none of the intermetatarsal neuromas were confirmed by sonography. A five-year follow-up study using a prospective case series 
design followed a total of 45 and assessed the effects of ultrasound guided ultrasound alcohol injections.[50] The study concluded that only 29% 
(n=13) remained symptom free at five-years although 33% were completely satisfied with the treatment and 27% satisfied with a few 
reservations. A total of 36% (n=16) required excision of the intermetatarsal neuroma. However, it was not clear from the article the 
concentration of alcohol injections used and number of injections. The authors also acknowledged that some of the data was collected 
retrospectively which may have led to some bias in reporting. Thus, the evidence presented in this study is also questionable and a more robust 
methodological design is necessary to inform clinical guidelines. 
Hughes et al. (2007) carried out a study in 101 participants with a single lesion. Subjects received a total of three to six intra-lesional injections 
of 20% alcohol and 0.5% bupivacaine hydrochloride at two week intervals. VAS and a modified scale from Johnson et al. (1988) were used to 
assess outcome during follow-up at 7-19 months. Seventeen patients (16.8%) reported a flogistic reaction. At baseline, the mean lesion diameter 
was 10mm (range 7-15mm) and at follow-up 7mm (range 5-11mm) with 84% completely satisfied and pain free with median VAS scores 
reducing from 8 units to 0 units (p<0.001).[10] However, although this is the first study where inferential statistics were used improving the 
external validity of the study, there are still methodological issues affecting internal validity with regards to no randomisation, no placebo-
control groups, non-standardisation of the number of injections used and a big range of time for outcome follow up (7-19 months). 
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Espinosa et al (2011) carried out a retrospective case series study in an orthopaedic clinical setting of 32 patients following diagnosis of 
intermetatarsal neuroma.[51] Patients reported the presence of symptoms for a mean of 27 months. Twenty-eight patients had unilateral neuroma 
and four bilateral. Patients were treated with 20% alcohol and 0.25% bupivacaine using a non-guided technique. Patients were followed up every 
second week and the injection repeated up to ten times if still symptomatic (66% [n=21/32] received four injections). Mean VAS at baseline was 
6.9 and this decreased to 5.2 after four injections. Post hoc analysis showed that seven patients reported a mean VAS of 1.2 by four weeks with 
the remaining (n=25) reporting a mean VAS of 6.9. Thus, the authors stated the treatment to be effective in 22% (n=7) of cases. The limitations 
are similar to previous studies with no control use, low number given that it was retrospective and no inferential statistics used in the analysis of 
the data. 
A study by Pasquali et al (2015) evaluating the effectiveness of alcohol injections was carried out in two centres and evaluated a total of 508 
patients.[52] The study was a retrospective cross-sectional study and analysed all alcohol injections over an 11 year period. A total of 14.2% 
(n=72) had bilateral neuromas. All patients were treated with 50% alcohol injections with 2% mepivacaine and had neuromas confirmed both 
clinically and with diagnostic ultrasound. VAS and patient satisfaction was recorded at the one year follow-up after the injection. Overall, 74.5% 
were satisfied with the outcome with a reduction in pain and improvements in quality of life. For those patients where the treatment had failed 
and an alternative treatment offered, 9.3% (n=50) had the neuroma surgically excised.[52] These results suggest a good level of satisfaction with 
alcohol injections, however the study design was retrospective with no comparisons made with a control group, hence there is a high risk of bias. 
The latest study by Perini et al (2016) was a retrospective cohort design with follow-up at 15-24 months of 220 patients (15% [n=33] males and 
85% [n=187] females).[53] The mean neuroma diameters were 5.4mm (range 4-9mm). All patients were diagnosed by clinical symptoms 
confirmed by sonography. Patients received a guided injection using 50% alcohol with 2% lidocaine. Patients received up to three treatments at 
two week intervals were pain using VAS was evaluated. A complete resolution of symptoms or a reduction of at least 50% of pain using VAS 
was reported in 72.3% (n=159) p<0.001. The results suggest a good and similar level of satisfaction to previous studies although again the 
research design is retrospective and no comparisons are made with a control group hence there is a high risk of bias. Another aspect of the study 
to consider is that the average size of the scanned neuromas was small. Thus, an RCT is necessary to draw definitive conclusions about the 
effectiveness of alcohol injections. 
4.1.2 Adverse Events 
All the papers in this review, except one[47], reported adverse events post sclerosing alcohol injections for the management of intermetatarsal 
neuroma. Hyer al al (2005), although no adverse events were reported, one must take into account that this study only included six participants 
and the concentration of alcohol used was at the lower end of 4%.[47] The other two studies using alcohol concentrations of 4% reported some 
level of adverse effects that was transient, that is, a flogistic reaction. Dockery (1999), in a study of 100 patients, reported that a common 
complaint post injection was the feeling of burning but did not present any data for this.[9] In the other study using a concentration of 4%, 
Mozena et al (2007) reported seven percent of post injection localised pain out of 42 patients that took part in the study.[49] 
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With regards to studies using alcohol concentrations of 20%, Musson et al (2012) reported post injection local pain in one percent of the 92 
patients that took part in this study with another one percent (n=1) reporting a major adverse event of anaphylaxis.[48] Hughes et al (2007) stated 
that 16.8% of 101 patients in his study suffered a transient local pain post injection with MRI reporting intense mid and forefoot marrow oedema 
that spontaneously settled after three weeks.[10] In a study with 32 participants, Espinosa et al (2011) reported that nine percent suffered a 
flogistic reaction.[51] 
For alcohol concentrations of 30%, Masala et al (2001) reported a localised transient pain in 78% of 23 patients that took part in the study with a 
further four percent (n=1) suffering other complications.[45] This was the second highest report of local adverse events of all the paper 
reviewed. In comparison, Fanucci et al (2004) reported a much lower figure of 15% with regards to local transient adverse events in this study 
with 40 participants.[1] 
At the highest alcohol concentrations of 50%, in a study of 508 participants, Pasquali et al (2015) reported a mean of 0.7 (range 0 to 2) for 
flogistic reactions.[52] However, although the value appears low making comparison with the other reports for adverse events is difficult. The 
highest report of adverse events was in the study by Perini et al (2016), the study included 220 participants of which 80.9% reported local short 
lived pain at the injection site.[53] This was the highest report of adverse events. 
Finally, although one study involving 42 participants reported a flogistic reaction in seven percent of cases, the concentration of alcohol used was 
not reported.[49] 
On face validity, for all studies presented, there was no pattern to suggest that using adrenaline with the local anaesthetic agent or guiding the 
injection had an effect. However, the highest reports of local transient post injection adverse events occurred at alcohol concentrations of 30% 
and 50%. 
Recommendations for clinical practice 
Clinicians should note that the research evidence to support alcohol injections is poor as all studies reported in this systematic review suggest a 
high risk of methodological bias. Until future research studies on the effectiveness of alcohol injections for intermetatarsal neuroma are able to 
provide robust evidence (for example, by using randomised control trial designs) it is recommended that health professionals consider using a 
stepwise approach to the management of intermetatarsal neuroma. The management for intermetatarsal neuroma should initially be based on 
other more evidence based treatments (e.g. steroid injections) prior to trying out this modality of treatment option with alcohol injections. 
Clinicians should also be aware that the evidence for the most effective percentage of alcohol concentration to inject still needs to be established, 
however they should note that at higher concentrations there appears to be an increase in adverse events although these are short lived. In 
addition, when deciding what concentration to use and whether to guide the injections, one should also take note that two animal studies reported 
no nerve damage regardless of alcohol concentrations used for extra-neural injections. With regards to intra-neural injections, one study reported 
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no effect up to alcohol concentrations of 30%. The other animal study reported that at alcohol concentrations of 25% a quarter of axons showed 
neural pathological damage; with alcohol concentrations of 50% signs of pathological nerve damage occurred to half of the axonal tissue in the 
samples examined. 
Recommendations for future research 
Randomised control trials comparing the effectiveness of various concentrations of alcohol injections against a control, of for example, the more 
established treatment of steroid injections are needed. The quality of these studies should be single or double blinded and investigate both short 
and long-term outcomes prospectively, with adequate power and ideally multi-centred. 
5 Conclusion 
Following an extensive review of the literature pertaining to the effectiveness of alcohol injections there appears to be some evidence to suggest 
that alcohol injections as a conservative treatment may be effective in reducing pain levels, quality of life and satisfaction with the treatment. 
Equally, other studies have suggested that the treatment of intermetatarsal neuroma with alcohol injection may not be effective. Alcohol 
injections appear to be safe although some studies report a short-term side effect of a flogistic reaction. There are also variances in the alcohol 
concentration used and guiding verses not guiding the injection using ultrasound imaging. Furthermore, some of the evidence may suggest a 
sclerosing histological effect of the nerve. However, all the studies reviewed present a research design offering a low level of evidence that is 
open to methodological biases and interpretation. Thus, this review found insufficient high-quality research evidence to afford conclusions on 
the management of intermetatarsal neuroma with alcohol sclerosing agent injections. 
The management of intermetatarsal neuroma remains a clinical challenge, with steroid injection in the short term supported more strongly by 
RCTs but long-term management remains an area where more research is required. Given the lack of high level evidence to support the effective 
management of intermetatarsal neuroma using the current range of reported treatments[22], a staged management approach as recommended by 
Bennett et al (1995) may be a logical treatment option until further research evidence to support the respective treatment options becomes 
available [8]. At present, alcohol injections could be included in this stepwise approach but more high-quality evidence is required. 
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Figure 1 study selection process. 
 
Table 1 full text articles excluded. 
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Reference Reason for exclusion 
Morgan et al. (2014)  Systematic Review  
Schereiber et al. (2011) Review  
Hetman (2005) Commentary 
Mazoch et al. (2014) Animal study 
 
*Arbitration by third author (GM) occurred only if a dispute between the two reviewers was not resolved 
 
Table 2 methodological breakdown of the studies. 
Autho
r 
(year) 
Study 
Desig
n 
Interve
ntion  
Partici
pant 
numbe
r 
Follo
w-up 
perio
d  
Outcome  Adverse events 
Docker
y 
(1999) 
Prospe
ctive 
case 
series 
4% 
alcohol & 
local 
anaestheti
cs with 
adrenalin 
No guided 
injection 
100 Mean 
13 
month
s 
(Rang
e 6 
month
s and 
2 
years) 
Satisfaction questionnaire 
N= (82%) reported complete 
resolution of symptoms 
N= (7%) reported some 
improvement of symptoms 
N= (11%) reported no 
improvement of symptoms 
 
No data was presented. The most 
common complaint was 
following the first injection with 
post injection burning sensation, 
increased ``pins and needles," and 
pain on the ball of the foot in the 
affected area after anaesthetic 
effect wore off. This increase in 
symptoms occurred during the 
first 48 hours following the first 
injection and decreased sharply 
thereafter. No other post injection 
complications were reported. AC
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Masala 
et al. 
(2001) 
Prospe
ctive 
case 
series 
30% 
alcohol 
& local 
anaesthe
tics with 
adrenali
n 
Guided 
injection 
23 36-48 
hours 
after 
injecti
on 
<H1>
3 
weeks 
7 
weeks  
Satisfaction questionnaire 
N=21 (91%) reported complete 
resolution of symptoms [n=3 
complete resolution within 3 
weeks; n=5 complete resolution 
within 40-50 days] 
N=2 (9%) reported no 
improvement of symptoms 
N=18 (78%) pain at injection site 
that disappeared within 3-4 days. 
N=1 (4%) other procedure related 
complications reported. 
Fanucc
i et al. 
(2004)  
Prospe
ctive 
case 
series 
30% 
alcohol 
& local 
anaesthe
tics 
Guided 
injection 
40 10 
month
s 
Johnson Scale 
N=21 (53%) reported complete 
satisfaction with treatment 
N=9 (23%) reported satisfied, but 
with minor complications 
N=6 (15%) were satisfied, but 
with major complications 
N=4 (10%) were dissatisfied and 
underwent surgery  
N=6 (15%) transitory plantar 
pain, due to the flogistic reaction. 
No other procedure related 
complications was reported. 
Hyer et 
al. 
(2005) 
Prospe
ctive 
case 
series  
4% 
alcohol 
& local 
anaesthe
tics with 
adrenali
n 
No 
guided 
injection 
6 Mean 
3465
0.3 
days 
Pain VAS 
Mean pain reduction 6.133.2 
 
Satisfaction questionnaire 
N=5 (83%) would recommend 
procedure to a friend 
No adverse events with the 
injections was reported. 
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Musso
n et al. 
(2012)  
Prospe
ctive 
case 
series 
20% 
alcohol 
& local 
anaesthe
tics 
Guided 
injection 
92 Mean 
14.3 
month
s 
(Rang
e 6-26 
month
s) 
 
Pain VAS 
Median pain VAS pre-procedure 
8 (range 4-10) 
Median pain VAS post-procedure 
4 (range 0-10) 
 
Satisfaction questionnaire 
Of 85 treatment courses with 2 
patients excluded for multiple 
neuromas: 
N=55 (66%) reported 
complete/partial resolution of 
symptoms [of these n=27 had 
complete resolution and n=28 
partial resolution] 
N=30 (35%) reported no 
improvement 
N=1 (1%) developed an allergic 
reaction with facial swelling and 
vomiting soon after the first 
treatment. N=1 (1%) found 
injection very painful and 
declined further treatment. N=1 
(1%) developed significant pain 
and swelling following the 
second injection so the third 
treatment was delayed by one 
week. There were no other 
complications and all other 
patients tolerated the treatment 
well. 
Mozen
a et al. 
(2007) 
Prospe
ctive 
case 
series 
4% 
alcohol 
& local 
anaesthe
tics with 
adrenali
n 
No 
guided 
injection 
42 Mean 
11 
month
s 
(Rang
e 2-24 
month
s)  
Satisfaction questionnaire 
N=16 (33%) reported complete 
resolution of symptoms 
N=14 (29%) reported an 
improvement of symptoms. 
N=3 (7%) reported a post 
injection short-term complication, 
two complained of pain that 
resolved within the first 24 hours, 
and one had some erythema 
around the injection area that 
resolved within 2 days. 
No other procedure related 
complications was reported. AC
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Gurdez
i et al. 
(2013) 
Prospe
ctive 
case 
series 
Alcohol 
concentr
ation not 
reported
. Also 
use of 
local 
anaesthe
tic or 
adrenali
n was 
not 
reported 
Guided 
injection 
45 Mean 
5 
years 
(range 
2.75-6 
years) 
Pain VAS 
Pain VAS pre-procedure 8a 
Pain VAS post-procedure 4a 
 
Pain rate 
N=13 (29%) reported pain free 
N=18 (40%) reported 
mild/moderate pain 
N=14 (31%) reported no 
difference 
 
Modified Johnson score 
N=15 (33%) reported complete 
satisfaction with treatment 
N=12 (27%) reported satisfied, 
but with minor reservations 
N=5 (11%) were satisfied, but 
with major reservations 
N=9 (9%) were dissatisfied 
N=4 (9%) I wish I had never had 
the injection 
N=12 (27%) reported 
complications. N=9 (20%) 
reported immense pain at the time 
of injection, despite local 
anesthetic infiltration. N=3 (7%) 
had extensive bruising at the 
injection site, and N=2 (4%) 
complained of ongoing numbness 
of the toes. 
Hughes 
et al. 
(2007) 
Prospe
ctive 
case 
series 
20% 
alcohol 
& local 
anaesthe
tics 
101 Mean 
10.5 
month
s 
(Rang
Pain VAS 
Median Pain VAS pre-procedure 
8 (interquartile range 7-8) 
N=17 (16.8%) reported plantar 
pain that settled after 2 days–3 
weeks (mean, 4.5 days). In one 
such case, post procedural MRI 
showed intense mid- and forefoot 
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Guided 
injection 
e 7-19 
month
s)  
Median Pain VAS post-procedure 
4 (interquartile range 0-1) 
 
Pain rateb 
N=84 (84%%) reported pain free 
N=8 (8%%) reported 
mild/moderate pain 
N=8 (8%) reported no difference 
 
Modified Johnson scoreb 
N=62 (62%) reported complete 
satisfaction with treatment 
N=24 (24%) reported satisfied, 
but with minor reservations 
N=5 (5%) were satisfied, but with 
major reservations 
N=3 (3%) were dissatisfied 
N=6 (6%) I wish I had never had 
the injection 
marrow oedema that 
spontaneously settled after 3 
weeks. 
No other procedure related 
complications was reported. 
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Pasqua
li et al. 
(2015) 
Retros
pective 
case 
series 
50% 
alcohol 
& local 
anaesthe
tics 
Guided 
injection 
508 1 year Pain VAS 
Mean Pain VAS pre-procedure 
8.7 (range 6-10) 
Mean Pain VAS post-procedure 
3.6 (range 0-9) 
 
Satisfaction questionnairec 
N=137 feet (25.3%) VAS Score 0 
N=263 feet (48.7%) VAS Score 
1-3 
N=140 feet (25.9%) little or no 
resolution of symptomsc 
Mean local inflammatory reaction 
was 0.7 (range, 0 to 2). There 
were no other local or systemic 
complications. 
Perini 
et al. 
(2016) 
Retros
pective 
case 
series 
50% 
alcohol 
& local 
anaesthe
tics 
Guided 
injection 
220  Mean 
19 
month
s 
(range 
15-24 
month
s) 
Pain VAS 
Median Pain VAS pre-procedure 
9 (interquartile range 8-10) 
Median Pain VAS post-procedure 
3 (interquartile range 0-6) 
 
Satisfaction questionnaires 
N=159 (72.3%) complete 
resolution of symptoms or a 
reduction of at least 50% of pain 
using VAS 
N=28 () complained of 
neuropathic pain 
N=178 (80.9%) short-living pain 
on the injection site was a 
constant complaint. 
No other procedure related 
complications was reported. 
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N=33 () complained of mixed 
neuropathic and nociceptive pain 
 
Limitation of daily living scale 
(score 0-3) 
Median pre-procedure 3 
(interquartile range 2-3) 
Median post-procedure 0 
(interquartile range 0-0) 
Espino
sa et al. 
(2011) 
Retros
pective 
case 
series 
20% 
alcohol 
& local 
anaesthe
tics 
No 
guided 
injection 
32 Range 
2-20 
weeks  
Pain VAS 
Mean Pain VAS pre-procedure 
6.9 (range 4-10) 
Mean Pain VAS post-procedure 
5.2 (range 0-10) 
 
Satisfaction with treatmentd 
N=7 (22%) reported successful 
treatment 
N=3 (9%) developed a transient 
intolerable pain from the local 
infiltration of alcohol and 
bupivacaine and did not receive 
the full 1-ml injection. 
No major complications, were 
reported. 
 
 
a Authors did not report if the VAS score was the mean or median. 
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b One patient could not be contacted. 
 
c No VAS score given 
 
d No validated satisfaction tool was used. 
 
 
Table 3 risk of bias in selected studies. 
 
RISK OF BIAS 
AUTHORS 
DOMAIN 
SEQUENCE 
GENERATIO
N 
ALLOCATION 
CONCEALMENT 
BLINDING OF 
PARTICIPANT
S 
BLINDING 
OF 
PERSONNEL 
BLINDING OF 
OUTCOME 
ASSESSORS 
INCOMPLETE 
OUTCOME DATA 
SELECTIVE 
OUTCOME 
REPORTING 
OTHER SOURCES 
OF BIAS 
Dockery 
(1999) 
HIGH RISK HIGH RISK HIGH RISK HIGH RISK HIGH RISK HIGH RISK UNCLEAR UNCLEAR 
Not randomly assigned No allocation concealment performed  Participants were not blinded 
Study personnel were not blinded Outcome assessor were not blinded 
‘Excluded from the study where any patient that discontinued therapy prior to the 3rd injection''  
No reference to study protocol No other sources of bias reported (ie: conflict of 
interest) 
Masalla et al. 
(2001) 
HIGH RISK HIGH RISK HIGH RISK HIGH RISK HIGH RISK UNCLEAR UNCLEAR UNCLEAR 
Not randomly assigned No allocation concealment performed  Participants were not blinded 
Study personnel were not blinded Outcome assessor were not blinded Unclear Unclear  Unclear  
HIGH RISK HIGH RISK HIGH RISK HIGH RISK HIGH RISK LOW RISK UNCLEAR UNCLEAR AC
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Fanucci et 
al.(2004) 
Not randomly assigned No allocation concealment performed  Participants were not blinded 
Study personnel were not blinded Outcome assessor were not blinded 
``Total of 160 injections were performed in 40 patients'' All cases were accounted in the provided outcome data  
No reference to study protocol No other sources of bias reported (ie: conflict of 
interest) 
Hyer et al. 
(2005) 
HIGH RISK HIGH RISK HIGH RISK HIGH RISK HIGH RISK HIGH RISK UNCLEAR UNCLEAR 
Not randomly assigned No allocation concealment performed  Participants were not blinded 
Study personnel were not blinded Outcome assessor were not blinded 
``Of the initial 8 patient eligible for this study, 2 patients (6 neuromas) were lost to final follow up'' 
No reference to study protocol No other sources of bias reported (ie: conflict of 
interest) 
Musson et al 
(2012) 
HIGH RISK HIGH RISK HIGH RISK HIGH RISK HIGH RISK HIGH RISK UNCLEAR UNCLEAR 
Not randomly assigned No allocation concealment performed  Participants were not blinded 
Study personnel were not blinded Outcome assessor were not blinded 
``Seventeen patients has incomplete pre-treatment and follow-up data, and were therefore excluded''. 
No reference to study protocol No other sources of bias reported (ie: conflict of 
interest) 
Mozena et al 
(2007) 
HIGH RISK HIGH RISK HIGH RISK HIGH RISK HIGH RISK LOW RISK UNCLEAR UNCLEAR Not randomly assigned No allocation concealment performed  Participants were not blinded 
Study personnel were not blinded Outcome assessor were not blinded 
All selected cases were accounted and reported in the results section.  No reference to study protocol 
No other sources of bias reported 
(ie: conflict of 
interest,  
HIGH RISK HIGH RISK HIGH RISK HIGH RISK HIGH RISK HIGH RISK UNCLEAR LOW RISK 
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Gurdezi et al. 
(2013) 
Not randomly assigned No allocation concealment performed  Participants were not blinded 
Study personnel were not blinded Outcome assessor were not blinded 
``60 patients had ultrasound guided alcohol injection for Morton’s neuroma between March 2004 and June 2007 at our institution. 45 of this patients were available for follow up''  
No reference to study protocol 
``Authorship declared no conflict of interest with respect to research authorship and publication of the article''. 
Hughes et al. 
(2007) 
HIGH RISK HIGH RISK HIGH RISK HIGH RISK HIGH RISK LOW RISK UNCLEAR UNCLEAR Not randomly assigned No allocation concealment performed  Participants were not blinded 
Study personnel were not blinded Outcome assessor were not blinded 
100 patients were contacted, but 1 patient could not be contacted'' No reference to study protocol 
No other sources of bias reported 
(ie: conflict of 
interest) 
Pasquali et al. 
(2015) 
HIGH RISK HIGH RISK HIGH RISK HIGH RISK HIGH RISK UNCLEAR UNCLEAR LOW RISK 
Not randomly assigned No allocation concealment performed  Participants were not blinded 
Study personnel were not blinded Outcome assessor were not blinded 
Unclear as resulted were presented as number of treated feet rather than number of treated patients at 1 year follow up.  
No reference to study protocol 
``Authorship declared no conflict of interest with respect to research authorship and publication of the article''. 
Perini et al. 
(2016) 
HIGH RISK HIGH RISK HIGH RISK HIGH RISK HIGH RISK HIGH RISK UNCLEAR LOW RISK 
Not randomly assigned No allocation concealment performed  Participants were not blinded 
Study personnel were not blinded Outcome assessor were not blinded 
`` 7 patients for incomplete dataset'' were excluded.  No reference to study protocol 
``Authorship declared no conflict of interest with respect to research authorship and publication of the article''. A
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Espinosa et al. 
(2011) 
HIGH RISK HIGH RISK HIGH RISK HIGH RISK HIGH RISK UNCLEAR UNCLEAR LOW RISK 
Not randomly assigned No allocation concealment performed  Participants were not blinded 
Study personnel were not blinded Outcome assessor were not blinded Unclear No reference to study protocol 
``No benefits in any form have been received or will be received from a commercial party related directly or indirectly to the subject of this article''.   
 
 
 
1A number of authors refer to a flogistic reaction but do not define what they mean by this. To clarify this a flogistic reaction will be taken as an 
inflammatory local response to injection with transient pain. 
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